Trium Capital discloses 1.76M MURA shares, sole voting power

Rhea-AI Filing Summary

Trium Capital LLP reports beneficial ownership of 1,760,097 ordinary shares of Mural Oncology plc, representing 10.16% of the outstanding class. The filing states Trium has sole voting and sole dispositive power over these shares, and that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The document identifies the security as ordinary shares with nominal value $0.01 and provides the issuer's principal office in Dublin, Ireland.

Positive

• Significant disclosed stake: 1,760,097 shares representing 10.16% of the class
• Clear control reporting: sole voting and sole dispositive power reported, simplifying ownership transparency
• Declared passive intent: Securities held in the ordinary course and not to influence control, consistent with Schedule 13G treatment

Negative

• None.

Insights

Financial Analyst

TL;DR: A >10% stake with sole voting and dispositive power is material disclosure but reflects a passive ownership declaration.

Trium Capital's reported 10.16% holding is large enough to warrant investor attention because it crosses typical 10% reporting thresholds that can affect float and takeover math. The holder asserts the position is in the ordinary course of business and not intended to influence control, which suggests a disclosure-driven filing rather than an activist intent. The filing does not disclose any derivative positions or arrangements, and all voting and dispositive powers are reported as sole, simplifying the ownership picture.

Corporate Governance Expert

TL;DR: This is a standard Schedule 13G disclosure indicating significant ownership without claimed intent to change control.

The statement confirms sole control over voting and disposition of 1,760,097 shares, which establishes clear governance influence potential despite the declarant's non-control intent. The certification that the shares were not acquired to influence control aligns with Schedule 13G treatment rather than a Schedule 13D. The filing lacks details on any agreements, board nominations, or strategic plans, limiting conclusions about future governance impact.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Mural Oncology plc

(Name of Issuer)

Ordinary shares, nominal value $0.01 per share

(Title of Class of Securities)

G63365103

(CUSIP Number)

08/22/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G63365103

1

Names of Reporting Persons

Trium Capital LLP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,760,097.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,760,097.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,760,097.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.2 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Mural Oncology plc
(b)	Address of issuer's principal executive offices: 10 EARLSFORT TERRACE, DUBLIN 2, IRELAND, D02 T380.
Item 2.
(a)	Name of person filing: Trium Capital LLP
(b)	Address or principal business office or, if none, residence: 60 Gresham Street, London, United Kingdom, EC2V 7BB
(c)	Citizenship: United Kingdom
(d)	Title of class of securities: Ordinary shares, nominal value $0.01 per share
(e)	CUSIP No.: G63365103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,760,097
(b)	Percent of class: 10.16 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,760,097
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,760,097
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Trium Capital LLP

Signature:	Fredrik Ostlund
Name/Title:	Chief Compliance Officer
Date:	09/02/2025

FAQ

How many MURA shares does Trium Capital LLP report owning?

Trium Capital reports beneficial ownership of 1,760,097 shares of Mural Oncology plc.

What percentage of Mural Oncology (MURA) does Trium Capital own?

The filing states a 10.16% ownership of the class.

Does Trium Capital have voting control over the reported shares of MURA?

Yes; the filing reports sole voting power and sole dispositive power over the 1,760,097 shares.

Is Trium Capital claiming an intent to influence control of Mural Oncology?

No; the certification states the securities are held in the ordinary course of business and not held to change or influence control of the issuer.

What type of SEC statement was filed by Trium Capital regarding MURA?

Trium Capital filed a Schedule 13G reporting its beneficial ownership of Mural Oncology ordinary shares.